“… 11 , 12 , 13 , 14 Furthermore, PROTAC’s selectivity can be greater than the binding selectivity of the ligands alone, allowing to discriminate between highly similar proteins or isoforms in ways that are not possible with occupancy-based inhibitors. 8 , 11 , 12 , 15 , 16 , 17 Within the past four years, potent and selective PROTACs have been designed to hijack either the von Hippel-Lindau (VHL) or cereblon (CRBN) E3 ligase against a target protein of interest. 18 , 19 Targets that have been shown to be degraded by PROTACs include members of bromodomain-containing proteins such as the BET proteins (Brd2, Brd3 and Brd4), 7 , 8 , 9 , 14 , 15 , 17 , 20 , 21 amongst other epigenetic protein classes; 22 , 23 , 24 , 25 , 26 protein kinases; 10 , 12 , 27 , 28 , 29 , 30 , 31 as well as non-bromodomain and non-kinase target proteins.…”